Moderna (MRNA) to Offer $500M in Common Stock

Moderna, Inc. (Nasdaq: MRNA) announced that it has commenced an underwritten public offering of $500 million in shares of common stock. In addition, Moderna expects to grant the underwriters a 30-day option to purchase up to an additional $75 million in shares of common stock in connection with the public offering. All shares of common stock will be offered by Moderna.

Moderna expects to use the net proceeds of the offering to fund clinical development and drug discovery in existing and new therapeutic areas; to fund further development of its mRNA technology platform and the creation of new modalities; and the remainder to fund working capital and other general corporate purposes.

Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

You May Also Be Interested In

• Gaxos.ai raises $3.6M through warrant exercise transaction
• NNN REIT adds two directors amid board succession planning
• Wrap Technologies prices $12M direct offering at $1.40 per share